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Abstract
Failure of the human heart to maintain sufficient output of blood for the demands of the
body, heart failure, is a common condition with high mortality even with modern therapeutic
alternatives. To identify molecular determinants of mortality in patients with new-onset heart
failure, we performed a meta-analysis of genome-wide association studies and follow-up
genotyping in independent populations. We identified and replicated an association for a
genetic variant on chromosome 5q22 with 36% increased risk of death in subjects with
heart failure (rs9885413, P = 2.7x10-9). We provide evidence from reporter gene assays,
computational predictions and epigenomic marks that this polymorphism increases activity
of an enhancer region active in multiple human tissues. The polymorphism was further
reproducibly associated with a DNA methylation signature in whole blood (P = 4.5x10-40)
that also associated with allergic sensitization and expression in blood of the cytokine TSLP
(P = 1.1x10-4). Knockdown of the transcription factor predicted to bind the enhancer region
(NHLH1) in a human cell line (HEK293) expressing NHLH1 resulted in lower TSLP expres-
sion. In addition, we observed evidence of recent positive selection acting on the risk allele
in populations of African descent. Our findings provide novel genetic leads to factors that
influence mortality in patients with heart failure.
Author Summary
In this study, we applied a genome-wide mapping approach to study molecular determi-
nants of mortality in subjects with heart failure. We identified a genetic variant on chro-
mosome 5q22 that was associated with mortality in this group and observed that this
variant conferred increased function of an enhancer region active in multiple tissues. We
further observed association of the genetic variant with a DNAmethylation signature in
blood that in turn is associated with allergy and expression of the gene TSLP (Thymic stro-
mal lymphoprotein) in blood. Knockdown of the transcription factor predicted to bind the
enhancer region also resulted in lower TSLP expression. The TSLP gene encodes a cytokine
that induces release of T-cell attracting chemokines from monocytes, promotes T helper
type 2 cell responses, enhances maturation of dendritic cells and activates mast cells.
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Development of TSLP inhibiting therapeutics are underway and currently in phase III
clinical trials for asthma and allergy. These findings provide novel genetic leads to factors
that influence mortality in patients with heart failure and in the longer term may result in
novel therapies.
Introduction
Heart failure (HF) is a common clinical condition in which the heart fails to maintain blood
circulation adequate to meet the metabolic demands of the body without increased cardiac fill-
ing pressures. HF is the result of chronic ventricular remodelling initiated by myocardial injury,
volume/pressure overload, or intrinsic cardiomyopathic processes. Progression of HF is a com-
plex process involving many tissues, driven by activation of neurohormonal pathways, which
induce gradual myocardial hypertrophy, ventricular dilation, and deterioration of cardiac func-
tion, often resulting in death from low cardiac output, arrhythmia, or thromboembolic compli-
cations [1]. Activation of such neurohormonal pathways in the short term increases cardiac
output when necessary. However, long-term activation results in accelerated ventricular
remodelling and myocyte death. Inhibitors of deleterious neurohormonal pathways, including
adrenergic [2–4] and renin-angiotensin-aldosterone (RAAS) [5–8] pathways have been shown
to improve ventricular function and survival in patients with HF and are the mainstay of cur-
rent pharmacological treatment of HF [9–10]. Despite advances in therapy with neurohor-
monal antagonists, mortality after onset of HF remains high [9–13] and continued progress to
identify additional therapeutic targets is needed.
Genome-wide association (GWA) studies have the potential to identify in an agnostic man-
ner genetic variants related to clinical outcomes in humans and has led to the identification of
novel pathways [14] and potential treatments [15] for cardiovascular traits. Heritable factors
have been shown to be predictive of mortality in certain heart failure patients [16]. We there-
fore implemented a genome-wide association approach to identify novel molecular determi-
nants of mortality in patients with new-onset HF.
Results
Two-stage GWA study
We expanded our previously published GWA study [17] of HF mortality with additional sam-
ples and extended follow-up in Stage 1. Stage 1 included 2,828 new-onset HF patients from five
community-based cohorts, thus representative of the general population of HF patients, as part
of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consor-
tium [18]: the Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health
Study (CHS), the Framingham Heart Study (FHS), the Health, Aging and Body Composition
(Health ABC) Study, and the Rotterdam Study (RS). Cohorts are described in detail in S1 Text.
HF was defined using international published criteria as outlined in S1 Table. Subjects in Stage
1 cohorts were of European ancestry, predominantly male, and approximately 20–30% had a
history of myocardial infarction at the time of HF diagnosis. Additional characteristics are
shown in Table 1. During an average follow-up time of 3.5 years, 1,798 deaths occurred. The
sample-size weighted average 1-year mortality rate was 28%. Among deaths, 51% were classi-
fied as cardiovascular, 19% were due to neoplasms, 10% were respiratory deaths, and the
remaining were due to other miscellaneous causes. Genotyping using high-density Illumina or
Affymetrix single nucleotide polymorphism (SNP) arrays, followed by imputation to the
Heart Failure GWAS
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HapMap CEU release 22 imputation panel was performed in each cohort. Population stratifi-
cation was assessed and corrected in each cohort as described in S1 Text. Association with
time to death following HF diagnosis was examined in each cohort using Cox proportional
hazards models with censoring at loss to follow-up. Mild inflation of test statistics was observed
only in the Framingham Heart Study (FHS) as shown in S1 Fig (λGC = 1.07, other
cohorts 1.03), and genomic control was applied in each individual study. In the meta-analy-
sis of all cohorts, there was no evidence of inflated test statistics overall (λGC = 1.00) as shown
in S2 Fig, so no further genomic control was needed. Results for all SNPs across the genome
are plotted in S3 Fig. Single nucleotide polymorphisms (SNPs) passing a significance threshold
specified a priori as P< 5.0x10-7, as used in our previous article [17], were carried forward to a
second stage of genotyping in independent cohorts.
Five SNPs on chromosome 5q22 and one SNP on chromosome 3p22 passed the pre-speci-
fied P-value threshold. Results for all six SNPs are shown in Table 2 and S3 Table. The five
SNPs on chromosome 5q22 were highly correlated (pairwise r2> 0.9). Two sentinel SNPs,
rs9885413 and rs12638540, on chromosomes 5q22 and 3p22, respectively, were next genotyped
in 1,870 European-ancestry subjects with new-onset HF from four independent cohorts in
Stage 2: Malmö Diet and Cancer, Malmö Preventive Project, Physicians’Health Study, and the
PROSPER trial. Characteristics of populations in Stage 2 are shown in S2 Table. During an
average sample-size weighted follow-up of 4.3 years in Stage 2 samples, 889 patients died. We
observed evidence of association with mortality for rs9885413 on chromosome 5q22
(P = 0.006) but not for the SNP rs12638540 (P = 0.18) which reached nominal significance in
our previous analysis [17]. Results for both SNPs are shown in Table 2. In the combined results
from Stages 1 and 2, rs9885413 was associated with a 36% relative increase in mortality per
minor allele (P = 2.7x10-9). There was no evidence for effect heterogeneity across cohorts in the
two stages (P for heterogeneity = 0.39) as shown in S4 Table. The SNP had a similar minor
allele frequency (MAF = 0.07) across cohorts. Information on cause-specific mortality was
available from death certificates in a subset of cohorts (S5 Table) and was explored descrip-
tively due well-known problems with substantial misclassification in death certificate data and
low power for agnostic GWAS of individual causes. The minor allele frequency was slightly
higher for several causes of death associated with heart failure, including renal, pulmonary and
endocrine mortality and death from ischemic heart disease.
Lack of association with myocardial traits
We next examined whether rs9885413 on chromosome 5q22 that was associated with HFmortal-
ity was also associated with differences in myocardial structure and function, which could poten-
tially mediate the association (S6 Table). In 12,612 individuals from the EchoGen Consortium
[19], the SNP was not associated with major echocardiographic characteristics. The SNP
rs9885413 was not associated with incident HF in 20,926 individuals from the general population
in the CHARGE-HF study [20], or with cardiac endocrine function, as determined by plasma levels
of atrial and B-type natriuretic peptides (all P> 0.05), in a GWA study of 5,453 individuals from
the population-basedMalmö Diet and Cancer study [21]. No association was observed with elec-
trocardiographic measures of cardiac conduction (n = 39,222) [22] or repolarization (n = 74,149)
[23], which confer risk of ventricular arrhythmia, or with sudden cardiac death in 4,496 sudden
death cases and over 25,000 controls from the general population (described in S1 Text).
Functional enhancer annotation
The lead SNP rs9885413 on chromosome 5q22 that was associated with mortality is located in
an intergenic region, 100 kb downstream of the gene SLC25A46, 114 kb upstream of
Heart Failure GWAS
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TMEM232, and 230 kb upstream of TSLP as shown in Fig 1. The SNP is not in linkage disequi-
librium with any known coding SNP in the 1000 Genomes Project database (no coding SNP
with r2> 0.01 to the sentinel SNP). We therefore sought to evaluate gene regulatory functions
of this SNP.
In 129 human tissues from the ROADMAP Epigenomics project [24], we studied whether
rs9885413 or strongly correlated SNPs (a total of 9 at r2> 0.8) are located in regulatory regions,
as determined by histone modification patterns. None of the 9 SNPs was located in an active
regulatory region in cardiac tissues (S7 Table), but rs9885413 was located in a predicted
enhancer in several epithelial or mesenchymal tissues, including keratinocytes, gastrointestinal
cell types and adipose cells (Fig 2 and S7 Table). Regulatory motif annotations in HaploReg
indicate that the SNP causes a change in a regulatory motif predicted to bind the transcription
factor NHLH1 as shown in S8 Table. Interestingly, NHLH1-null mice have been shown to be
predisposed to premature, adult-onset unexpected death in the absence of signs of cardiac
Table 1. Characteristics of cohorts in stage 1.
ARIC ARIC2 CHS FHS Health ABC RS RS2
HF sample size 691 84 838 249 173 748 45
Age at HF (years) 67.3 (6.6) 68.8 (6.5) 82.4 (6.1) 80.7 (9.6) 79.1 (3.8) 79.6 (8.0) 73.7 (8.6)
Male sex (%) 60.1 58.3 56.3 47.8 61.8 48.8 68.9
Body mass index (kg/m2) 29.5 (5.9) 28.7 (6.3) 27.0 (4.6) 28.5 (5.4) 26.5 (4.3) 27.2 (4.1) 27.1 (4.0)
Diabetes (%) 28.7 29.8 18.1 17.7 20.8 8.6 11.1
Hypertension (%) 58.5 53.7 52.3 76.3 79.8 81.0 73.3
Current smoking (%) 28.6 33.3 8.4 10.4 7.5 18.6 26.7
History of MI (%) 25.2 26.2 5.4 27.7 24.9 28.1 28.9
Follow-up time (years) 3.9 (3.9) 4.1 (4.0) 3.5 (2.4) 1.8 (1.9) 3.0 (2.7) 3.9 (3.7) 3.6 (2.6)
Mortality rate, 1 year 0.25 0.22 0.28 0.34 0.27 0.30 0.25
All-cause mortality (n, %) 327 (47.3) 42 (50.0) 606 (72.3) 156 (62.7) 87 (50.3) 556 (74) 24 (53)
Age, body mass index and follow-up time are presented as mean (standard deviation). Categorical variables are presented as percentages. Body mass
index, diabetes, hypertension and smoking refer to the nearest study exam prior to heart failure diagnosis whereas age, follow-up time, mortality rate and
all-cause death refer to the time of HF diagnosis. Mortality rate refers to the 1-year Kaplan-Meier estimate, with censoring at end of or loss to follow-up.
The prevalence of myocardial infarction in CHS is low, because this was an exclusion criterion at the study baseline. MI, Myocardial infarction.
doi:10.1371/journal.pgen.1006034.t001
Table 2. Association of genetic polymorphisms with HFmortality.
SNP Stage 1 Stage 2 Combined Heterogeneity
Chr Alleles MAF HR (95% CI) P HR (95% CI) P HR (95% CI) P I2 P
rs12638540 3p22 G / A 0.04 1.50 (1.28–1.75) 4x10-7 1.10 (0.89–1.37) 0.18 1.35 (1.19–1.54) 3.08x10-6 0 0.53
rs9885413 5q22 T / G 0.07 1.40 (1.23–1.58) 1x10-7 1.25 (1.05–1.49) 0.006 1.36 (1.23–1.51) 2.65x10-9 0.15 0.39
rs12658193 5q22 T / G 0.07 1.39 (1.23–1.58) 2x10-7 - - - -
rs11956079 5q22 T / C 0.07 1.39 (1.23–1.58) 2x10-7 - - - -
rs10069077 5q22 T / C 0.07 1.39 (1.23–1.58) 2x10-7 - - - -
rs10068260 5q22 T / A 0.06 1.42 (1.24–1.62) 2x10-7 - - - -
Results for SNPs with P-value < 5x10-7 in stage 1 are presented with minor/major alleles, minor allele frequency (MAF) and effect estimate (HR, hazard
ratio) with 95% conﬁdence intervals (95% CI) per minor allele from multivariable models adjusting for sex and age at the time of diagnosis. The index SNP
at each locus was carried forward to stage 2. Effect heterogeneity was evaluated across the combined stage 1 and 2 samples. Chr, Chromosome.
doi:10.1371/journal.pgen.1006034.t002
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structural or conduction abnormalities, in particular when mice were exposed to stress [25].
Little is known about the function of NHLH1, but it is widely expressed in human tissues and
has been shown to regulate expression of key inflammatory genes [26].
To experimentally test the effect of rs9885413 on enhancer activity, the 100 bp region flank-
ing the SNP (50 bp on either side) was cloned into a reporter vector and transfected into
HEK293 cells expressing NHLH1 (S1 Text). Luciferase activity measured after 24 hours was
4-fold higher with a construct corresponding to the risk allele as compared to the wild-type
allele (S4 Fig, P< 0.001), indicating that the risk allele of rs9885413 substantially increases
enhancer activity.
Effects on DNAmethylation
We next explored the association of rs9885413 with DNA methylation at the locus, providing
functional evidence of epigenetic association and regulation of gene expression. DNA methyla-
tion was determined by a microarray assaying in total over 480 000 CpG methylation sites in
whole blood samples from 2408 participants of the FHS. Of the 84 CpG methylation sites on
the microarray within +/- 500 kb of the SNP, two were significantly associated with rs9885413:
cg21070081 (beta 0.017 per T allele, P = 9.0x10-69) and cg02061660 (beta -0.015 per T allele,
P = 4.5x10-40), thus constituting strong methylation quantitative trait loci (mQTLs) at the
locus. Other, correlated SNPs at the locus were more strongly associated with each of these
mQTLs as shown in S5 Fig: rs244431 for cg21070081 (P = 6.7x10-369) and rs72774805 for
cg02061660 (P = 7.0x10-85). The SNP rs72774805 (perfect proxy SNP rs3844597 used) but not
rs244431 was associated with heart failure mortality (P = 3.3x10-3 and 0.08, respectively), indi-
cating that the methylation site cg02061660 is more strongly related to the underlying signal
for heart failure mortality. The association of rs9885413 with lower probability of methylation
Fig 1. Regional association plot for HF mortality at the 5q22 locus. The plot covers the genomic region from 450 kb upstream of the SNP to 650 kb
downstream. Diamonds represent SNPs. The large black diamond represents the SNP with the lowest P-value (rs9885413), with the P-value from the
combined meta-analysis presented. Diamond color represents strength of pairwise correlation with the strongest SNP. Red represents r2 0.8, orange
represents r2 0.5–0.8, yellow represents r2 0.2–0.5, and white represents r2 < 0.2. Recombination rate is plotted in the background and known genes are
represented in the bottom of the plot. Positions refer to NCBI build 36. SNP correlations and recombination rates were obtained from HapMap release 22.
doi:10.1371/journal.pgen.1006034.g001
Heart Failure GWAS
PLOSGenetics | DOI:10.1371/journal.pgen.1006034 May 5, 2016 6 / 19
at cg02061660 was replicated in 731 participants from the Rotterdam study (beta -0.029 per T
allele, P = 1.7x10-11). Adjustment for cell types from direct measurement instead of estimates
from methylation patterns did not abolish the association (beta -0.029 per T, P = 1.2x10-6).
Interestingly, differential methylation at this CpG site was also correlated with a SNP at the
locus previously associated with allergic sensitization [27] (rs10056340, P = 4.7x10-29 for
Fig 2. Epigenomic marks indicating enhancer activity at the 5q22 locus. Histone marks in samples from the ROADMAP Epigenomics Project at the
enhancer overlapping the lead SNP rs9885413 in heart tissue (left ventricle) and in tissues with evidence of an active enhancer at the locus. Histone marks
are monomethylation (H3K4Me1) of the fourth residue (lysine) and acetylation of the 27th residue (H3K27Ac) of histone H3. Positions refer to NCBI build 36.
doi:10.1371/journal.pgen.1006034.g002
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mQTL), suggesting a link to inflammatory disease. This SNP was also modestly correlated with
rs9885413 (r2 = 0.28) and associated with heart failure mortality (P = 0.01). The association of
cg02061660 with rs9885413 (P = 0.52) and rs10056430 (P = 0.87) was abolished in analyses
conditioning for rs72774805, for which the association was also markedly attenuated
(P = 7.0x10-33 and 2.1x10-46, respectively) indicating that these correlated SNPs may reflect the
same underlying signal.
Effects on gene expression
We further assessed the association of rs9885413 with gene expression. No gene was signifi-
cantly associated with rs9885413 in the diverse tissues from the Gene-Tissue Expression
(GTEx) project [28] after correction for multiple tests (S1 Text, S9 Table), although conclu-
sions were limited by a small sample size.
We next assessed association of the SNP with gene expression in two large datasets with
each of the tissues most relevant for the phenotype under study: heart tissue and whole blood.
We observed no convincing evidence of association (S1 Text, S10 Table) with gene expression
in 247 left ventricular samples from patients with advanced heart failure (n = 116) undergoing
transplantation and from unused donors (n = 131). Finally, we tested the association of
rs9885413 with the expression of genes at the locus in whole blood from 5257 FHS participants
[29], and with DNAmethylation at cg02061660 among 2262 FHS participants. All five genes at
the locus (Fig 1) except TMEM232 were expressed in blood. We did not observe association of
the SNP rs9885413 with any transcript, but expression of one gene (TSLP) was significantly
associated with the methylation status of cg02061660 (P = 1.1x10-4).
The TSLP gene encodes a cytokine released from epithelial cells that induces release of T
cell-attracting chemokines from monocytes, promotes T helper type 2 cell responses, enhances
maturation of dendritic cells and activates mast cells. It has also been linked to angiogenesis
and fibrosis. A monoclonal antibody targeting and inhibiting TSLP is currently in clinical
phase III trials for asthma and allergic inflammation after a promising phase II trial [30–32]. In
the myocardium, the TSLP gene has very low expression (S10 Table) but expression has been
described in mature myocardial fibroblasts, which are abundant in the myocardium but of sub-
stantially smaller volume than cardiomyocytes and likely contribute little to the overall myo-
cardial RNA pool [31,32].
To examine whether the transcription factor NHLH1 affects the expression of any of the
five genes in the locus (Fig 1), we knocked down NHLH1 in HEK293 cells using siRNAs. A
50% decrease in NHLH1 mRNA levels was seen 48 hours after transfection, confirming effi-
cient knock down (p<0.05, S6A Fig). TSLP was the only gene at the locus affected by NHLH1
knock down, showing a 30% decrease compared to cells transfected with negative control
siRNA (p<0.05, S6A Fig). Moreover, we observed a dose-response relation between level of
NHLH1 knockdown and expression of TSLP in HEK293 cells (r2 = 0.74, p<0.0001, S6B Fig).
Population genetic analysis
Finally, distribution of the risk allele of rs9885413 in human populations was assessed using
data from HapMap phase II. The derived (non-ancestral) T allele (risk allele for mortality) was
highly differentiated among human populations (S7 Fig) having risen to an allele frequency of
0.59 in a Nigerian population (HapMap YRI sample) but only 0.06 in a European population
(CEU sample). The fixation index (Fst), a measure of population differentiation in allele fre-
quencies, for comparison of YRI and CEU was 0.48 and more extreme Fst was observed in only
2.4% of SNPs in the HapMap phase 2 dataset. Consistent results were observed for another sig-
nature of recent positive selection, based on longer runs of haplotype homozygosity in carriers
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of the derived allele (standardized integrated haplotype score -0.766 in YRI, where negative
score values indicate longer haplotypes on the background of the derived allele) [33]. These
observations are consistent with positive selection in recent human history, with a selective
sweep resulting in high frequency of the derived allele in western African populations. These
findings are of particular interest as HF mortality is well known to be higher in populations of
African ancestry, although the current study has not tested for the association with HF mortal-
ity in such populations [34].
Discussion
We identified a SNP on chromosome 5q22 associated with increased mortality in subjects with
HF. Although previous genome-wide association studies have described hundreds of loci asso-
ciated with risk of disease onset, few have examined prognosis in subjects with manifest dis-
ease. This approach has the potential to generate targets for novel disease-modifying
medications. Through a series of analyses in silico and in vitro we show that the SNP is located
in an enhancer region, and confers increased activity of this enhancer.
Interestingly, mice deficient in the transcription factor NHLH1 predicted to bind a motif in
this enhancer region have been reported to be predisposed to premature, adult-onset unex-
pected death in the absence of signs of cardiac structural or conduction abnormalities. NHLH1
has also been shown to regulate expression of key inflammatory cytokines such as interleukin-
6 and tumor necrosis factor α. The SNP was not associated with any electrocardiographic,
endocrine, or echocardiographic marker of increased risk in the general population, suggesting
a mechanism specific to heart failure, an extracardiac pathway of importance in cardiac patho-
physiology, or interaction with therapy for heart failure which we were unable to further test
given the inception cohort design of this study. We also did not observe any robust eQTL asso-
ciations for the SNP in heart. The SNP was however associated with a DNA methylation signa-
ture in whole blood that was also associated with a SNP previously associated with allergy, and
with expression of the cytokine TSLP in blood. Knockdown of NHLH1 also resulted in lower
expression of TSLP in HEK293 cells. This non-coding SNP may thus exert an influence on
TSLP expression via altered NHLH1 enhancer function and DNAmethylation at the methyla-
tion site cg02061660. Detailed characterization of causal variants and different association sig-
nals at the locus would however require finemapping and sequence data.
The TSLP cytokine is released from epithelial cells and fibroblasts and is considered important
in initiation of inflammatory responses to tissue damage, particularly in the type 2 T-helper
(Th2) pathways. Th2 pathways are central in the response to extracellular parasites but also play
a key role in the pathophysiology of allergies and hypersensitivity reactions. A small subset of HF
is known to be caused by Th2-mediated inflammation (eosinophilic cardiomyopathy), yet Th2
cells have received limited attention in HF pathophysiology. Recent experimental work impli-
cates an important role of T-helper cells in HF progression for both systolic and diastolic heart
failure, but has mainly focused on type 1 T-helper pathways [35,36]. It remains unclear if the
mechanism for rs9885413 is through a specific etiology characterized by high mortality such as
eosinophilic cardiomyopathy or a pathway involved in outcomes with manifest disease. The lack
of association with HF incidence suggests that it may not act through incidence of a specific etiol-
ogy, although firm conclusions are limited by sample size. We did not observe significant associa-
tions of the SNP with gene expression in any tissue. It is possible that adequately powered
samples with a specific cell subtype in a specific context is needed to detect such associations, as
illustrated by a recent study which only observed certain eQTLs with single-cell but not across
averaged cells [37]. Indeed, baseline expression of TSLPwas low in our samples, and is induced
by tissue injury, microbes, viruses and proinflammatory cytokines [38].
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Evidence of recent positive selection in individuals of African descent suggests that the HF
risk allele may have been beneficial in some environments in recent human history. Inflamma-
tory pathways are enriched for signals of recent positive selection, reflecting that infectious dis-
ease has been an important cause of mortality throughout recent evolution. Genes such asHBB
and APOL1 have also been reported to have been subject to recent positive selection in Africa by
conferring protection against infectious diseases such as Malaria and Trypanosomiasis (sleeping
sickness) [39], and APOL1 alleles have also been linked to cardiovascular disease [40]. As cardio-
vascular disease and heart failure often presents after reproductive age, increased mortality in
such patients would not be expected to exert purifying (negative) selective pressure. Whether
SNPs at 5q22 contribute to higher mortality in subjects of African ancestry remains to be shown.
Thus, although additional work is needed to further clarify the tissues and pathways per-
turbed by this genetic variant and the mechanisms linking it to mortality in HF patients, the
current findings implicate rs9885413 as a novel marker of increased risk among patients with
HF. Complementary epigenomic evidence demonstrated candidate regions and genes, which
may be mediators in cardiac pathophysiology and potential therapeutic targets to improve
prognosis in patients with HF.
Materials and Methods
Genome-wide association study stage 1
A genome-wide association (GWA) study was performed in a total of 2,828 subjects of Euro-
pean ancestry with HF from seven samples collected within five large community-based pro-
spective cohort studies including the Atherosclerosis Risk in Communities (ARIC and ARIC2)
Study, the Cardiovascular Health Study (CHS), the Framingham Study (FHS), the Health ABC
(Health ABC) study and the Rotterdam Study (RS and RS2). Sample characteristics, data col-
lection and clinical definitions have been described previously and are summarized in S1 Text.
[41–46] First diagnosis of heart failure (new-onset) was ascertained using a variety of methods
based on international published criteria, as detailed in S1 Table. Mortality was ascertained
from telephone contacts with relatives and from medical records, death certificates and/or
municipal records (S1 Text).
Genotyping was performed using commercially available assays for genome-wide SNP
detection. Imputation of non-genotyped SNPs was performed using CEU reference panels of
SNP correlations from the HapMap project phase II (S1 Text), to characterize a total of 2.5
million SNPs. Imputation quality was assessed for each SNP from the ratio of observed over
expected variance of allele dosage.
All-cause mortality following initial HF diagnosis was examined for association with addi-
tive allele dosage of each genotyped or imputed SNP using Cox proportional hazards models,
with censoring at the end of or loss to follow-up. Models were adjusted for age at diagnosis,
sex, and recruitment site in multicenter cohorts. In the family-based FHS, Cox models were
implemented with clustering on pedigree to account for relatedness. Genomic control was
applied to results from each cohort. Cohort-specific GWA results were combined using fixed
effects meta-analysis with inverse variance weights. SNPs were excluded from cohort-level
analyses if exhibiting implausible beta coefficients (< -5 or> 5) and from the meta-analysis
for low heterozygosity (sample size-weighted minor allele frequency 0.03, corresponding
to< 100 minor allele carriers with an endpoint).
Stage 2 genotyping in independent samples and combined analysis
SNPs passing a P-value threshold defined a priori as P< 5.0x10-7 in the genome-wide stage 1
were carried forward to the second stage with targeted genotyping in 1,870 HF patients from
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four independent cohorts. For 2.5 million tests, this threshold limits the expected number of
genome-wide false positives to approximately 1, assuming statistical independence of tests. The
second stage included four independent cohorts; the Malmö Diet and Cancer Study (MDCS),
the Malmö Preventive Project (MPP), the Physicians’Health Study (PHS) and the Prospective
Study of Pravastatin in the Elderly at Risk (PROSPER) [47–50]. Heart failure ascertainment
and time of death in these cohorts was similar to in stage 1 cohorts, as shown in S1 Table and
S1 Text. Genotyping was performed as outlined in S1 Text. Association analyses and meta-
analysis of results were performed as in the first stage. Meta-analysis of stage 1 and 2 was per-
formed, and a combined P-value< 5.0x10-8 was considered significant. Heterogeneity was
assessed across the combined stage 1 and 2 cohorts using Cochran’s Q test for heterogeneity,
computed as the sum of the squared deviations of each study’s effect from the weighted mean
over the study variance, and the I2 test, the percentage of total variation across studies that is
due to heterogeneity rather than chance (I2 = [Q—df] / Q) [51, 52].
In silico studies of effect on cardiac structure and function
The association of replicated SNPs with measures of cardiac structure and function was evalu-
ated from summary results of the following GWA consortia: EchoGen [19], CHARGE-HF
[20], CHARGE-QRS [22], natriuretic peptides in 5453 subjects from the Malmö Diet and Can-
cer study [21], QT-IGC [23], and the CHARGE Sudden Cardiac Death consortium (manu-
script in preparation). Each of these consortia is described in S1 Text.
Interrogation of functional motifs
The correlation of replicated SNPs with known coding SNPs was examined in the databases for
the 1000 Genomes Project and phase III of the HapMap project, using SNAP [53]. The location
of SNPs in relation to regulatory motifs was explored using histone methylation patterns gener-
ated as part of the ROADMAP Epigenomics project [24]. Enhancers were identified in each of
the 129 ROADMAP tissues using the ChromHMM algorithm [54] from patterns of mono-
methylation (H3K4Me1) of the fourth residue (lysine) and acetylation of the 27th residue
(H3K27Ac) of histone H3. The location of SNPs in relation to transcription factor binding sites
was assessed in silico using HaploReg version 4.1 (http://www.broadinstitute.org/mammals/
haploreg/haploreg.php) [55] and the UCSC Genome Browser (http://genome.ucsc.edu). In
HaploReg, position weight matrices (PWMs; probabilistic representations of DNA sequence)
were computed with p-values based on literature sources and ENCODE ChIP-Seq experiments
as previously described [55], and only instances where a motif in the sequence passed a thresh-
old of P< 4−7 were considered. The NHLH1-binding motif was retrieved into HaploReg from
the manually curated TRANSFAC database.
In vitro assessment of enhancer activity
Complementary DNA oligonucleotides corresponding to the 100 bp genomic region flanking
rs9885413 (50 bp on either side of the SNP) were cloned into the luciferase reporter vector
pGL3-Promoter (Promega, Madison, WI) using the MluI and BglII sites. Two different sets of
oligos were cloned, one corresponding to the major allele of rs9885413 (pGL3P-G) and one to
the minor allele (pGL3P-T). Oligonucleotide sequences were as following: major allele sense:
CGCGTCCTGCCTCACATAATCTTTTTGTTTGTCCCCCTGAAATGGATTCTCA
GCTGTTGCCCAAACATTTCATCTTAGCGTTCCAGGTTTGAACTCGCCCTCACGA,
minor allele sense: CGCGTCCTGCCTCACATAATCTTTTTGTTTGTCCCCCTGAAA
TGTATTC TCAGCTGTTGCCCAAACATTTCATCTTAGCGTTCCAGGTTTGAA
CTCGCCCTCACGA, and the corresponding antisense sequences. The reporter vectors were
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co-transfected with the pRL-null vector at a ratio of 10:1 into HEK293 cells using Lipofecta-
mine LTX (Life Technologies) according to the manufacturer’s instructions. 24 hours post--
transfection, luciferase activity was assayed using the Dual-Luciferase Reporter Assay System
(Promega) and Glomax 20/20 Luminometer (Promega). The signal from the reporter vector
was normalized to the signal from the pRL-null vector.
Gene expression in heart
Samples of left ventricular cardiac tissue from patients undergoing cardiac surgery were geno-
typed for the SNP rs9885413 and for all five transcripts within +/- 500 kb of the SNP. Samples
of cardiac tissue were acquired from patients from the MAGNet consortium (http://www.med.
upenn.edu/magnet/). Gene expression levels were determined using the Affymetrix ST1.1 gene
expression array (Affymetrix, Santa Clara, CA, USA) in a cohort including 247 heart samples.
Genotyping was performed using the Illumina OmniExpress array. Left ventricular free-wall
tissue was harvested at time of cardiac surgery from subjects with heart failure undergoing
transplantation or from unused transplant donors. In all cases, the heart was perfused with
cold cardioplegia prior to cardiectomy to arrest contraction and prevent ischemic damage. Tis-
sue specimens were then obtained and frozen in liquid nitrogen. Genomic DNA from left ven-
tricle was extracted using the Gentra Puregene Tissue Kit (Qiagen) according to
manufacturer’s instruction.
Total RNA was extracted from left ventricle using the miRNeasy Kit (Qiagen) including
DNAse treatment on column. RNA concentration and quality was determined using the Nano-
Vue Plus spectrophotometer (GE Healthcare) and the Agilent 2100 RNA Nano Chip (Agilent).
For all samples, genome-wide SNP genotypes were generated using the Illumina OmniExpress
Array. Caucasian Ancestry was verified using multi-dimensional scaling of genotypes. For
Gene expression array experiments, the Affymetrix ST1.1 Gene array was used. Data were nor-
malized using the Robust Multi-array Average algorithm and batch effects were adjusted for
using ComBat. Transcript expression levels were considered significantly higher than back-
ground noise if expression values from robust multiarray analysis in at least 10% of either cases
or controls exceeded of the 80% quantile of expression of genes on the Y-chromosome in
female hearts (5.24). Associations of expression levels for expressed genes with SNP genotypes
were tested using a likelihood ratio test. Specifically, we fit a linear regression model Y = β0 +
β1D + β2g + β3(g x D) where Y is the log2 transformed expression level of a given probe, g is
the genotype (coded as 0, 1, and 2) of the test SNP, and D is heart failure disease status (D = 1
for heart failure cases and D = 0 for unused donor controls). Association between the probe
and test SNP was assessed by testing H0: β2 = β3 = 0 using a likelihood ratio test. Significance
of the test statistic was evaluated by comparing with a Chi-squared distribution with two
degrees of freedom. All models were additionally adjusted for age, gender, and study site.
DNAmethylation and gene expression in whole blood
The association of the SNP rs9885413 with DNA methylation was examined in 2408 partici-
pants from the FHS Offspring cohort. Methylation at cytosine-guanine dinucleotides (CpG) at
the 5q22 locus (+/-500 kb from rs9885413) were ascertained from a gene-centric DNA methyl-
ation array (Infinium HumaMethylation450 BeadChip, Illumina, San Diego, CA, USA) which
allows interrogation of 485,512 methylation sites across the genome. The array has coverage of
at least one methylation site near 99% of RefSeq genes and 96% of CpG islands. Briefly, bisul-
fite-treated genomic DNA (1 μg) from peripheral blood samples underwent whole-genome
amplification, array hybridization and scanning according to manufacturer instructions. Geno-
typing of rs9885413 was performed as described in S1 Text. Association of rs9885413 and the
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methylation probe cg02061660 with expression of the five genes at the locus (+/-500 kb from
rs9885413) was examined from microarray data (Affymetrix Human Exon Array ST 1.0) in
5257 participants from the FHS Offspring cohort and Third Generation cohort. Procedures for
RNA extraction, processing and analysis have been described previously (28). Linear mixed
effect (LME) models were fit accounting for familial correlation, cell count heterogeneity and
technical covariates to account for batch effects using the pedigreemm package in R [56]. Spe-
cifically, the mQTL model utilized a two-step approach: first, the DNA methylation beta-value
(ratio of methylated probe intensity to total probe intensity) was residualized with adjustment
for age, sex, cell count proportions (imputed using the Houseman method for granulocytes,
monocytes, B-lymphocytes, CD4+ T lymphocytes, CD8+ T lymphocytes and NK cells) [57],
measured technical covariates (row, chip, column), and the family structure covariance matrix.
Second, DNAmethylation residuals were specified as dependent variable, SNP genotype dos-
age as independent variable with additional adjustment for 558 SVAs (surrogate variable analy-
sis) [58] and ten principal components from eigenstrat [59] to account for unmeasured batch
effects. The eQTL models similarly residualized gene expression with adjustment for age, sex,
imputed cell count proportions (imputed in Offspring Cohort participants utilizing gene
expression markers of cell count proportions developed from the Third Generation partici-
pants with both gene expression and measured complete blood counts), and family structure
covariance matrix. The residual of gene expression was specified as dependent variable and
SNP dosage as independent variable adjusted for 20 PEER (probabilistic estimation of expres-
sion residuals) factors [60] to account for unmeasured technical and batch effects in the gene
expression data. The eQTMmodels specified gene expression residual as dependent variable
and DNA methylation residual as independent variable adjusted for 20 methylation SVAs and
20 expression SVAs to account for unmeasured technical and batch effects.
Replication of the association of rs9885413 with cg02061660 including the same covariates
in the model as in FHS was attempted in blood samples from 750 randomly selected partici-
pants of the Rotterdam study (RS3) not included in the GWA stage, where information from
the same DNAmethylation array as FHS was available. DNA was extracted, bisulfite-treated
using the Zymo EZ-96 DNA-methylation kit (Zymo Research, Irvine, CA, USA) and hybrid-
ized to arrays according to manufacturer instructions. During quality control samples showing
incomplete bisulfite treatment were excluded (n = 5) as were samples with a low detection rate
(<99%) (n = 7), or gender swaps (n = 4). Probes with a detection P-value>0.01 in>1% sam-
ples, were filtered out. A total number of 474,528 probes passed the quality control and the fil-
tered β values were normalized with DASEN implemented in the wateRmelon package in R
statistical software. Genotyping was performed using the Illumina 610quad array. Cell counts
were estimated using the same method as in FHS and also directly measured on a Coulter AcT
Diff II Hematology Analyzer (Beckman Coulter, Brea, CA) for granulocytes, monocytes, lym-
phocytes). Models including both estimated and directly measured cell counts were explored.
siRNA-mediated knock down of NHLH1
HEK293 cells were seeded at 100,000 cells/well in a 6-well plate the day before transfection.
Cells were transfected using Lipofectamine and 50 nM of siRNA designed to target human
NHLH1 or negative control siRNA (Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions. After 48 hours, cells were harvested and total RNA extracted
using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. cDNA was synthesized using the RevertAid H- First Strand cDNA Synthesis Kit
(Thermo Fischer Scientific, Waltham, MA, USA) using random hexamer primers and qPCR
was performed with TaqMan assays for NHLH1, TMEM232, SLC25A4, WDR36, TSLP,
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CAMK4 and GAPDH on a StepOne Plus Real-Time PCR System (Life Technologies). Gene
expression was normalized to GAPDH and expressed relative to cells transfected with negative
control siRNA according to the ΔΔCt-method [61].
Population genetic analysis
The frequencies of ancestral and derived alleles of rs9885413 were examined in populations
from the International HapMap Project (http://www.hapmap.org/) [62] and the Human
Genome Diversity Project (HGDP, http://hagsc.org/hgdp/) [63]. The fixation index (Fst) was
estimated as described by Weir and Cockerham [64], based on allele frequencies in HapMap
stage II as also previously described [65]. The integrated haplotype score (iHS) was calculated
from HapMap stage II data as described by Voight et al (http://haplotter.uchicago.edu/) [33].
Allele frequency distributions in HGDP populations were visualized using the HGDP selection
browser (http://hgdp.uchicago.edu/) [66].
Ethics statement
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Supporting Information
S1 Text. Supplementary Materials, Methods and Results.
(DOCX)
S1 Fig. Quantile-quantile plots for individual genome-wide association studies of HF mor-
tality. Plotted on the x-axis are expected P-values under the null hypothesis and on the y-axis
the observed P-values before genomic control has been applied.
(PDF)
S2 Fig. Quantile-quantile plot for meta-analysis of genome-wide association studies of HF
mortality. Plotted on the x-axis are expected P-values under the null hypothesis and on the y-
axis the observed P-values.
(PDF)
S3 Fig. HF mortality association results for 2.5 million SNPs across 22 autosomes in stage 1
cohorts. Each dot represents one SNP. The x-axis shows physical position by chromosome and
the y-axis–log10 (P-value). The vertical dotted line indicates the a priori specified significance
threshold for SNPs to be carried forward to stage 2 (P< 5.0x10-7).
(PDF)
S4 Fig. Increased enhancer activity by the lead SNP.HEK293 cells were transfected with
either empty vector (pGL3P) or vectors containing the major (pGL3P-G) or minor (pGL3P-T)
allele of rs9885413 together with 100 bp flanking the SNP. Luciferase activity from the vectors
was measured after 24 hours and normalized to that of a pRL-null vector. N = 3. P< 0.001.
(PDF)
S5 Fig. Association of rs9885413 with DNAmethylation. The plot covers the genomic region
of +/-1 million bases from each CpG methylation. P-values refer to association of each SNP
with two CpG methylation sites on chromosome 5q22: cg02061160 (top panel) and
cg21070081 (bottom panel). Circles represent SNPs. The purple circle represents the SNP asso-
ciated with heart failure mortality (rs9885413). Circle color represents strength of pairwise cor-
relation with rs9885413, with r2 according to the inset. CpG sites are illustrated below the
Heart Failure GWAS
PLOSGenetics | DOI:10.1371/journal.pgen.1006034 May 5, 2016 14 / 19
regional plot, as is the location of the SNP associated with allergic sensitization (rs10056340).
Recombination rate is plotted in the background and known genes are represented in the bot-
tom of the plot. Positions refer to NCBI build 36. SNP correlations and recombination rates
were obtained from the 1000 Genomes pilot and HapMap release 22, respectively. The plot was
created using LocusZoom (http://locuszoom.sph.umich.edu/locuszoom/).
(PDF)
S6 Fig. siRNA-mediated knock down of NHLH1.HEK293 cells were transfected with siRNA
targeted against NHLH1 and expression of the five genes surrounding rs9885413 were ana-
lyzed by qPCR. Expression levels were normalized to the housekeeping gene GAPDH and
expressed relative to cells transfected with negative control (NC) siRNA. Results are from three
separate experiments with triplicates in each sample group. p<0.05 in two sample t-tests. A)
Fold change for NHLH1 and individual genes at the locus. B) Dose-response relation of
NHLH1 knockdown and TSLP expression.
(PDF)
S7 Fig. Distribution of rs9885413 alleles in HGDP populations. Relative allele frequencies of
the ancestral (G, blue) and derived (T, yellow) alleles of rs9885413 presented as pie slices across
populations in the Human Genome Diversity Project (HGDP).
(PDF)
S1 Table. Methods of heart failure ascertainment and diagnosis across cohorts. Included
non-hospitalized deaths but not morbid events. European Society of Cardiology. In a vali-
dation sample as previously described [26]. †Signs and symptoms included in Framingham cri-
teria. ‡Cardiac structure and function including cardiomegaly, dilated ventricle, decreased
systolic function, or segmental wall-motion abnormalities. §Pharmaceutical treatments include
the prescribing of diuretics, digoxin, or vasodilator.
(DOCX)
S2 Table. Characteristics of stage 2 cohorts. Age, body mass index and follow-up time are
presented as mean (standard deviation). Categorical variables are presented as percentages.
Body mass index, diabetes, hypertension and smoking refer to the nearest study exam prior to
heart failure diagnosis whereas age, follow-up time, mortality rate and all-cause death refer to
the time of HF diagnosis. Mortality rate refers to the 1-year Kaplan-Meier estimate, with cen-
soring at loss to follow-up. MI: Myocardial infarction.
(DOCX)
S3 Table. Results for all SNPs with P< 1.0x10-5. Genome position (POS) refers to NCBI
build 36. CHR, chromosome. STR, strand. CA, coded allele. A2, non-coded allele. N, sample
size. BETA, beta estimate. SE, standard error of beta estimate. P, P-value.
(DOCX)
S4 Table. Cohort-specific results for SNPs in combined stages 1 and 2. CHR, chromosome.
CA, coded allele. A2, non-coded allele. Caf, coded allele frequency. N, sample size. Beta, beta
estimate. Se, standard error of beta estimate. P, p-value.
(DOCX)
S5 Table. Allele frequency distribution across major causes of mortality.
(DOCX)
S6 Table. In silico studies of associations of rs9885413 with cardiac structure and function.
(DOCX)
Heart Failure GWAS
PLOSGenetics | DOI:10.1371/journal.pgen.1006034 May 5, 2016 15 / 19
S7 Table. Enhancer annotations in the ROADMAP Epigenomics Project. Enhancer regions
in the 129 tissues from the ROADMAP Epigenomics Project, as determined from the
ChromHMM algorithm from patterns of monomethylation of the fourth residue (lysine) of
histone H3 (H3K4Me1). Enhancers overlapping the lead SNP on chromosome 5q22
(rs9885413) and strongly correlated SNPs (r2> 0.8), with enhancers overlapping the lead SNP
shown in bold.
(DOCX)
S8 Table. Location of rs9885413 in the predicted NHLH1 binding site.  The two alleles of
the SNP rs9885413.
(DOCX)
S9 Table. Association of rs9885413 with gene expression in the GTEx Project. Association
of rs9885413 with expression of the five genes at the chromosomal locus in 13 tissues from the
Gene-Tissue Expression Project with data available in> 60 samples. Empirical P-values were
computed using a permutation approach as described in documentation for the GTEx project
(http://www.gtexportal.org). N/A, no results available in GTEx. Effect direction is presented
for associations with P 0.1.
(DOCX)
S10 Table. Association of rs9885413 with gene expression in human heart. Association of
rs9885413 with expression of the five genes at the locus on chromosome 5q22 in 247 human
heart samples from 116 patients with advanced heart failure (HF) and 131 unused transplant
donor hearts (controls). Transcript expression levels were considered significantly higher than
background noise if expression values from robust multiarray analysis in at least 10% of either
cases or controls exceeded of the 80% quantile of expression of genes on the Y-chromosome in
female hearts (5.24). Positive direction indicates higher expression with the risk (minor) allele
of rs9885413.
(DOCX)
Acknowledgments
A detailed list of acknowledgments is provided in the Supplementary Materials.
Author Contributions
Conceived and designed the experiments: JGS JFF ACM RSV NLS. Performed the experiments:
JGS JFF OG XWMMo RJ BO. Analyzed the data: JGS JFF OG XWMMe RJ BO. Wrote the
paper: JGS. Data collection and analysis in the participating genome-wide association and
functional studies: ARIC study: ACM DA EB. CHARGE-SCD/ CHARGE-QRS study: NS
PvdH. CHS study: JCB KMR KDT BMP NLS. Functional enhancer annotation and siRNA
knockdown: JGS OG XWMK BO LAB CNC. Health ABC: AK SBK YL JBu. FHS: MMe RJ
YAW JN SD CY CL DL LAC RSV. MAGNet: MMo XS JBr CSM KBM TPC. MDC/MPP: JGS
MS. PHS: JBW HDS JMG LD. PROSPER: ST DJS BMB IF JWJ. RS: JFF SL BHCS AH AGU
JBvM AD OHF. QT-IGC: CNC.
References
1. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature 2008; 451: 919–928. doi:
10.1038/nature06798 PMID: 18288181
2. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of con-
trolled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart
Heart Failure GWAS
PLOSGenetics | DOI:10.1371/journal.pgen.1006034 May 5, 2016 16 / 19
failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF).
MERIT-HF Study Group. JAMA 2000; 283: 1295–1302. PMID: 10714728
3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353; 9–13.
PMID: 10023943
4. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on
morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
N Engl J Med 1996; 334: 1349–1355. PMID: 8614419
5. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart fail-
ure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J
Med 1987; 316: 1429–1435. PMID: 2883575
6. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection
fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302. PMID: 2057034
7. Pitt B, Zannad F, RemmeWJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on mor-
bidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Inves-
tigators. N Engl J Med 1999; 341: 709–717. PMID: 10471456
8. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan
on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet
2003; 362: 759–766. PMID: 13678868
9. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the inci-
dence of and survival with heart failure. N Engl J Med 2002; 347: 1397–1402. PMID: 12409541
10. Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A. Survival trends in men and
women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987–2003 from
the Swedish Hospital Discharge Registry. Eur Heart J 2009; 30: 671–678. doi: 10.1093/eurheartj/
ehn541 PMID: 19109351
11. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitaliza-
tion and mortality rates for Medicare beneficiaries, 1998–2008. JAMA 2011; 306: 1669–1678. doi: 10.
1001/jama.2011.1474 PMID: 22009099
12. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and
outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251–259. PMID:
16855265
13. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved
ejection fraction in a population-based study. N Engl J Med 2006; 355: 260–269. PMID: 16855266
14. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, et al. From noncoding vari-
ant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010; 466: 714–719. doi: 10.1038/
nature09266 PMID: 20686566
15. Cohen JC. Emerging LDL therapies: Using human genetics to discover new therapeutic targets for
plasma lipids. 2010; J Clin Lipidol 7: S1–5.
16. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk pre-
diction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J
2014; 35: 2010–2020. doi: 10.1093/eurheartj/eht439 PMID: 24126876
17. Morrison AC, Felix JF, Cupples LA, Glazer NL, Loehr LR, Dehghan A, et al. Genomic variation associ-
ated with mortality among adults of European and African ancestry with heart failure: the cohorts for
heart and aging research in genomic epidemiology consortium. Circ Cardiovasc Genet 2010; 3: 248–
255. doi: 10.1161/CIRCGENETICS.109.895995 PMID: 20400778
18. Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, et al. Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analy-
ses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet 2009; 2: 73–80. doi:
10.1161/CIRCGENETICS.108.829747 PMID: 20031568
19. Vasan RS, Glazer NL, Felix JF, LiebW, Wild PS, Felix SB, et al. Genetic variants associated with car-
diac structure and function: a meta-analysis and replication of genome-wide association data. JAMA
2009; 302: 168–178. doi: 10.1001/jama.2009.978-a PMID: 19584346
20. Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, et al. Association of genome-wide
variation with the risk of incident heart failure in adults of European and African ancestry: a prospective
meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) con-
sortium. Circ Cardiovasc Genet 2010; 3: 256–266. doi: 10.1161/CIRCGENETICS.109.895763 PMID:
20445134
21. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, et al. Assessment of
conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart
Heart Failure GWAS
PLOSGenetics | DOI:10.1371/journal.pgen.1006034 May 5, 2016 17 / 19
failure and atrial fibrillation. J Am Coll Cardiol 2010; 56: 1712–1719. doi: 10.1016/j.jacc.2010.05.049
PMID: 21070922
22. Sotoodehnia N, Isaacs A, de Bakker PI, Dorr M, Newton-Cheh C, Nolte IM, et al. Common variants in
22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet 2010; 42:
1068–1076. doi: 10.1038/ng.716 PMID: 21076409
23. Arking DE, Pulit SL, Crotti L, van der Harst P, Munroe PB, Koopmann TT, et al. Genetic association
study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nat
Genet 2014; 46: 826–836. doi: 10.1038/ng.3014 PMID: 24952745
24. Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature
2015; 518: 317–330. doi: 10.1038/nature14248 PMID: 25693563
25. Cogliati T, Good DJ, Haigney M, Delgado-Romero P, Eckhaus MA, KochWJ, et al. Predisposition to
arrhythmia and autonomic dysfunction in Nhlh1-deficient mice. Mol Cell Biol 2002; 22: 4977–4983.
PMID: 12077327
26. Yang IV, Alper S, Lackford B, Rutledge H, Warg LA, Burch LH, et al. Novel regulators of the systemic
response to lipopolysaccharide. Am J Respir Cell Mol Biol 2011; 45: 393–402. doi: 10.1165/rcmb.
2010-0342OC PMID: 21131441
27. Bønnelykke K, Matheson MC, Pers TH, Granell R, Strachan DP, Alves AC, et al. Meta-analysis of
genome-wide association studies identifies ten loci influencing allergic sensitization. Nat Genet 2013;
45: 902–6. doi: 10.1038/ng.2694 PMID: 23817571
28. GTEx consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013; 45: 580–585.
doi: 10.1038/ng.2653 PMID: 23715323
29. Zhang X, Joehanes R, Chen BH, Huan T, Ying S, Munson PJ, et al. Identification of common genetic
variants controlling transcript isoform variation in human whole blood. Nat Genet 2015; 47: 345–52.
doi: 10.1038/ng.3220 PMID: 25685889
30. Gauvreau GM, O’Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, et al. Effects of an anti-TSLP
antibody on allergen-induced asthmatic responses. N Engl J Med 2014; 370: 2102–10. doi: 10.1056/
NEJMoa1402895 PMID: 24846652
31. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther
2009; 123: 255–78. doi: 10.1016/j.pharmthera.2009.05.002 PMID: 19460403
32. Ying G, Zhang Y, Tang G, Chen S. Functions of thymic stromal lymphopoietin in non-allergic diseases.
Cell Immunol 2015; 295: 144–9. doi: 10.1016/j.cellimm.2015.03.006 PMID: 25880106
33. Voight BF, Kudaravalli S, Wen X, Pritchard JK. A map of recent positive selection in the human
genome. PLoS biology 2006; 4: e72. PMID: 16494531
34. Shah S. Heart failure with preserved ejection fraction in African Americans. Ethn Dis 2012; 22: 432–
438. PMID: 23140073
35. Hofmann U, Frantz S. Role of lymphocytes in myocardial injury, healing, and remodeling after myocar-
dial infarction. Circ Res 2015; 116: 354–67. doi: 10.1161/CIRCRESAHA.116.304072 PMID: 25593279
36. Laroumanie F, Douin-Echinard V, Pozzo J, Lairez O, Vinel C, Delage C, et al. CD4+ T cells promote the
transition from hypertrophy to heart failure during chronic pressure overload. Circulation 2014; 129:
2111–24. doi: 10.1161/CIRCULATIONAHA.113.007101 PMID: 24657994
37. Wills QF, Livak KJ, Tipping AJ, Enver T, Goldson AJ, Sexton DW, et al. Single-cell gene expression
analysis reveals genetic associations masked in whole-tissue experiments. Nat Biotechnol 2013; 31:
748–52. doi: 10.1038/nbt.2642 PMID: 23873083
38. Takai T. TSLP expression: cellular sources, triggers, and regulatory mechanisms. Allergol Int 2012;
61: 3–17. doi: 10.2332/allergolint.11-RAI-0395 PMID: 22270071
39. Karlsson EK, Kwiatkowski DP, Sabeti PC. Natural selection and infectious disease in human popula-
tions. Nat Rev Genet 2014; 15: 379–93. doi: 10.1038/nrg3734 PMID: 24776769
40. Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG, et al. Increased burden of cardio-
vascular disease in carriers of APOL1 genetic variants. Circ Res 2014; 114: 845–50. doi: 10.1161/
CIRCRESAHA.114.302347 PMID: 24379297
41. Investigators ARIC. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am
J Epidemiol 1989; 129: 687–702. PMID: 2646917
42. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular Health
Study: design and rationale. Ann Epidemiol 1991; 1: 263–276. PMID: 1669507
43. Dawber T, Meadors GF, Moore FE, Epidemiologic approaches to heart disease: the Framingham
study. American Journal of Public Health 1951; 41: 279–286. PMID: 14819398
44. Feinleib M, Kannel WB, Garrison RJ, The FraminghamOffspring Study. Design and preliminary data.
Preventive Medicine 1975; 4: 518–525. PMID: 1208363
Heart Failure GWAS
PLOSGenetics | DOI:10.1371/journal.pgen.1006034 May 5, 2016 18 / 19
45. Hofman A, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, IkramMA, et al. The Rotter-
dam Study: 2014 objectives and design update. Eur J Epidemiol 2013; 28: 889–926. doi: 10.1007/
s10654-013-9866-z PMID: 24258680
46. Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, et al. Epide-
miology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composi-
tion study. Arch Intern Med 2009; 169: 708–715. doi: 10.1001/archinternmed.2009.40 PMID:
19365001
47. Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O. Atrial fibrillation in the Malmo Diet and
Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol 2010; 25: 95–
102. doi: 10.1007/s10654-009-9404-1 PMID: 19936945
48. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA vari-
ants, and the development of type 2 diabetes. N Engl J Med 2008; 359: 2220–2232. doi: 10.1056/
NEJMoa0801869 PMID: 19020324
49. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly
individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:
1623–1630. PMID: 12457784
50. Djousse L, Driver JA, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of
heart failure. JAMA 2009; 302: 394–400. doi: 10.1001/jama.2009.1062 PMID: 19622818
51. CochranWG. The combination of estimates from different experiments. Biometrics 1954; 10: 101–
129.
52. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002;
21: 1539–1558. PMID: 12111919
53. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: a web-based
tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938–
2939. doi: 10.1093/bioinformatics/btn564 PMID: 18974171
54. Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat Meth-
ods 2012; 9: 215–216. doi: 10.1038/nmeth.1906 PMID: 22373907
55. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory
motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012; 40: D930–934. doi:
10.1093/nar/gkr917 PMID: 22064851
56. Vazquez AI, Bates DM, Rosa GJM, Gianol D, Weigel KA. Technical note: an R package for fitting gen-
eralized linear mixed models in animal breeding. J Anim Sci 2010; 88: 497–504. doi: 10.2527/jas.2009-
1952 PMID: 19820058
57. Houseman EA, AccomandoWP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNAmeth-
ylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 2012; 13: 86. doi:
10.1186/1471-2105-13-86 PMID: 22568884
58. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis.
PLoS genetics 2007; 3: e161.
59. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analy-
sis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904–9. PMID:
16862161
60. Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of expression residuals
(PEER) to obtain increased power and interpretability of gene expression analyses. Nat Protoc 2012;
7: 500–7. doi: 10.1038/nprot.2011.457 PMID: 22343431
61. Pfaffl MW. A newmathematical model for relative quantification in real-time RT-PCR. Nucleic Acids
Res 2001; 29: e45. PMID: 11328886
62. International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299–
1320. PMID: 16255080
63. Li JZ, Absher DM, Tang H, Southwick AM, Casto AM, Ramachandran S, et al. Worldwide human rela-
tionships inferred from genome-wide patterns of variation. Science 2008; 319: 1100–1104. doi: 10.
1126/science.1153717 PMID: 18292342
64. Weir BS, Cockerham CC. Estimating F-statistics for the analysis of population structure. Evolution
1984; 38: 1358–70.
65. Kosova G, Pickrell JK, Kelley JL, McArdle PF, Shuldiner AR, Abney M, et al. The CFTRMet 470 allele
is associated with lower birth rates in fertile men from a population isolate. PLoS genetics 2010; 6:
e1000974. doi: 10.1371/journal.pgen.1000974 PMID: 20532200
66. Pickrell JK, Coop G, Novembre J, Kudaravalli S, Li JZ, Absher D, et al. Signals of recent positive selec-
tion in a worldwide sample of human populations. Genome research 2009; 19: 826–837. doi: 10.1101/
gr.087577.108 PMID: 19307593
Heart Failure GWAS
PLOSGenetics | DOI:10.1371/journal.pgen.1006034 May 5, 2016 19 / 19
